B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CTRB1

MOLECULAR TARGET

chymotrypsinogen B1

UniProt: P17538NCBI Gene: 15046 compounds

CTRB1 (chymotrypsinogen B1) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CTRB1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1rottlerin3.2625
2bisindolylmaleimide ix3.1422
3staurosporinone2.7715
4razaxaban2.4811
5indigo2.087
6Bortezomib0.691

About CTRB1 as a Drug Target

CTRB1 (chymotrypsinogen B1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented CTRB1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CTRB1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.